Skip to main content
OpenTrials
Completed

NCT Number: NCT00590525

Inflammation as a Predictor in Cardioversion of Atrial Fibrillation

The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of inflammation. Recently a high CRP level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. We are conducting this study with patients such as yourself with atrial fibrillation who are planning to undergo cardioversion to determine what sort of relationship exists between CRP levels and atrial fibrillation. We will then look at success rates of converting atrial fibrillation to normal sinus rhythm, compared to patients' CRP levels.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Creighton University Medical Center

Omaha, Nebraska, 68131, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Atrial fibrillation patients referred for DC cardioversion
  • On stable medical therapy

Exclusion criteria

  • Known chronic inflammatory states such as infections, rheumatoid arthritis or known vasculitides.
  • Patients having undergone recent surgery or who are on steroid therapy for any reason will be excluded.

Treatment and study plan

Cardioversion

Procedure

Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark

Primary outcomes

  1. We hypothesize that a higher hsCRP is associated with higher failure rates in patients undergoing cardioversion for atrial fibrillation

    Time frame: 1 month

Secondary outcomes

  1. secondary endpoint will be if a new inflammatory disease state is diagnosed at the one-month mark.

    Time frame: 1 month

Sponsors and collaborators

Lead sponsor

Creighton University

Other

Registry information

Important dates

Study start
2004
Primary completion
2009
Study completion
2009
First posted
Jan 10, 2008
Registry last updated
Dec 1, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.